Month: April 2020

LUXEMBURGO, April 13, 2020 (GLOBE NEWSWIRE) — Tenaris S.A. (NYSE, México: TS y MTA Italia: TEN) anunció que, en respuesta al escenario adverso de precios del petróleo y gas en caída, sobreoferta sin precedentes en el mercado petrolero, y restricciones a las operaciones derivadas de la crisis del COVID-19, la sociedad está reestructurando sus operaciones en los Estados Unidos.Las plantas de Tenaris en Koppel y Ambridge, PA, Brookfield, OH, y Baytown, TX, han sido o serán temporalmente cerradas hasta tanto las condiciones de mercado mejoren.  Adicionalmente, Tenaris llevará a cabo reducciones de personal y ajustará niveles de producción en sus otras plantas en línea con la demanda de mercado.  Algunas de las declaraciones que aparecen en este comunicado de prensa son “declaraciones a futuro”. Las declaraciones a futuro están basadas...

NEW HAVEN, Conn., April 13, 2020 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today provided an update regarding the impact of the COVID-19 pandemic on its overall business continuity, including clinical trials, supply chain, and discovery research.Throughout the ongoing COVID-19 pandemic, Arvinas remains committed to keeping employees and their families safe and to reduce the number of people exposed to the virus. Arvinas also remains committed to continuing to create a new class of drugs based on targeted protein degradation, including continued development of the company’s PROTAC® protein degraders currently in ongoing clinical trials.In early March 2020, Arvinas activated business continuity plans to minimize business...

BURLINGTON, Mass., April 13, 2020 (GLOBE NEWSWIRE) — LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, announced today Q1 2020 preliminary, unaudited results and withdrew prior annual guidance for 2020 due to the potential impact of COVID-19.Q1 2020 Preliminary ResultsSales of $30.4mm to $30.6mmOperating income of $4.2mm to $4.4mmEarnings of $0.15 to $0.16 per diluted shareCash balance of $30.6mm and no long-term debt at March 31, 2020The COVID-19 pandemic began to negatively impact sales in the second half of March.  Due to the unpredictable magnitude and duration of the COVID-19 pandemic, the Company is withdrawing its previously announced annual guidance for 2020.The Company will release its first quarter 2020 financial results, as well as additional information related to the impact...

MEXICO CITY, April 13, 2020 (GLOBE NEWSWIRE) — Terrafina (”TERRA”) (BMV: TERRA13), a leading Mexican industrial real estate investment trust (“FIBRA”), externally advised by PGIM Real Estate and dedicated to the acquisition, development, leasing and management of industrial real estate properties in Mexico, announced today that:In light of the emergency situation in Mexico related to COVID-19, and the social distancing measures dictated by the Mexican Government, the National Banking and Securities Commission (CNBV) issued a resolution to grant temporary administrative easing measures to issuers in the Mexican market. Among other matters, the CNBV extended the deadline for the submission of annual financial information to July 8, 2020. Therefore, Terrafina has made the decision to postpone until further notice the annual ordinary...

RALEIGH, N.C., April 13, 2020 (GLOBE NEWSWIRE) — PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its first quarter 2020 results after the market closes on Thursday, April 30, 2020. The Company will also host a conference call on Friday, May 1, 2020 at 9:00 a.m. (ET) to discuss the results with members of the investment community.To participate via telephone, investors and analysts should dial (877) 930-8062 within the United States or (253) 336-7647 outside the United States approximately 10 minutes prior to the call start time. The conference ID for the call is 7450977. An audio replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 within the United States or (404) 537-3406 outside the United States. The replay ID is 7450977.A live audio broadcast will be available...

Gaithersburg, MD, April 13, 2020 (GLOBE NEWSWIRE) — Verus International, Inc. (“Verus” or the “Company”) (OTCQB: VRUS)) today announced financial results for its fiscal 2019 fourth quarter and fiscal year ended October 31, 2019. In conjunction with this release, the Company is also providing additional details on its strategy for the upcoming fiscal 2020 financial year.For Q4 2019, revenue set an all-time record of $4.7 million, an increase of 116% over the $2.2 million reported in Q4 2018.For fiscal 2019, management is noting the following items of importance:Revenue set an all-time record of $13.6 million, an increase of 135% over the $5.8 million reported in fiscal 2018.Gross profit margin was 15.2%, approximately 230 basis-points higher than the 12.9% reported in fiscal 2018.Operating expenses of $6.2 million were $3.2 million...

Conference Call Scheduled for 8:30 a.m. Eastern TimeWEST PALM BEACH, Fla., April 13, 2020 (GLOBE NEWSWIRE) — Affiliated Managers Group, Inc. (NYSE: AMG) will report financial and operating results for the first quarter ended March 31, 2020 on Monday, April 27, 2020. A conference call will be held at 8:30 a.m. Eastern time on the same day.                               In addition to quarterly results, the conference call may include discussion of management’s expectations of future financial and operating results. Jay C. Horgen, President and Chief Executive Officer, and Thomas M. Wojcik, Chief Financial Officer, will host the session.Parties interested in listening to the conference call should dial 1-877-407-8291 (U.S. calls) or 1-201-689-8345 (non-U.S. calls) shortly before the call begins.The conference call will also be available...

NEW YORK, 13 avr. 2020 (GLOBE NEWSWIRE) — Cellectis (Euronext Growth : ALCLS ; Nasdaq : CLLS), une société biopharmaceutique de stade clinique spécialisée dans le développement d’immunothérapies fondées sur des cellules CAR-T allogéniques ingénierées (UCART), annonce la nomination de Carrie Brownstein, M.D., au poste de Directrice médicale. Le Dr Brownstein supervisera la recherche et le développement cliniques pour les programmes UCART de Cellectis en phase clinique. Le Dr Brownstein quitte Celgene pour rejoindre Cellectis, forte d’une solide expérience en hématologie et pathologies myéloïdes. Le Dr Brownstein est basée sur le site de Cellectis à New York et rejoint le comité exécutif de l’entreprise.« Nous sommes ravis que le Dr Brownstein apporte à Cellectis sa grande expertise industrielle et son remarquable leadership au moment...

SAN FRANCISCO, April 13, 2020 (GLOBE NEWSWIRE) — Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera“) has announced that it will not proceed with the previously announced acquisition of Stero Biotechs, Ltd. (“Stero”), and that Stero and Kalytera have terminated the Letter of Intent relating to the acquisition.“Although Kalytera will not proceed with the acquisition of Stero, we are in active discussions with other companies to expand and diversify our operations,” stated Robert Farrell, the Company’s President and CEO.About Kalytera TherapeuticsKalytera Therapeutics, Inc. (“Kalytera“) seeks to establish a leading position in the development of novel medicines for a range of important unmet medical needs.Website Home: https://kalytera.co/News and Insights: https://kalytera.co/news/Investors: https://kalytera.co/investors/Cautionary...

RICHMOND, Va., April 13, 2020 (GLOBE NEWSWIRE) — Kinsale Capital Group, Inc. (NASDAQ: KNSL) announced today that it will release financial results for the first quarter of 2020 after the market closes on Thursday, April 30, 2020.The Company will host a conference call to discuss its results with analysts and investors on Friday, May 1, 2020, beginning at 9:00 a.m. (Eastern Time). The release will also be available on the Company’s website, www.kinsalecapitalgroup.com.To access the conference call, dial (844) 239-5282, conference ID# 4841629, or via the Internet by going to www.kinsalecapitalgroup.com and clicking on the “Investor Relations” link. Please visit the website at least 15 minutes before the call to register and download and install any necessary audio software. A replay of the call will be available on the website until...